Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.59 |
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101300 | 0.89 | MEN1 (0.72) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| SCHEMBL1138318 | 0.87 | MEN1 (0.79) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| SCHEMBL16225886 | 0.87 | MEN1 (0.79) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| SCHEMBL1138320 | 0.87 | MEN1 (0.79) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| SCHEMBL219432 | 0.86 | MEN1 (1.00) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| SCHEMBL2794662 | 0.86 | MEN1 (1.00) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| SCHEMBL27485345 | 0.84 | MEN1 (0.96) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| Hydrochloric Acid SCHEMBL7006476 | 0.84 | MEN1 (0.96) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| Fluoride SCHEMBL27959930 | 0.84 | MEN1 (0.96) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| Hydrochloric Acid SCHEMBL11456225 | 0.84 | MEN1 (0.96) | MEN1KMT2AOPRD1USP2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2578569-B1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARM CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| EP-2578569-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| WO-2011148888-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | あすか製薬株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | HRH2, HRH4, HRH1 | MEN1 2318/4885KMT2A 524/4885OPRD1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.